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Comments on “In Vitro and in
Vivo Estrogenicity of UV
Screens”
Schlumpf et al. (1) reported on the in vitro
and in vivo “estrogenicity” of six ultraviolet
(UV) filters: benzophenone-3 (Bp-3),
homosalate (HMS), 4-methyl-benzylidene
camphor (4-MBC), octyl-methoxycinnamate
(OMC), octyl-dimethyl PABA (OD-PABA),
and butyl-methoxydibenzoylmethane (B-
MDM). The authors concluded that “UV
screens should be tested for endocrine activi-
ty, in view of possible long-term effects in
humans and wildlife.” 
There is international consensus that in
vitro data should serve only for screening
purposes and that they are not suited for
conclusions regarding risk assessment. The
interpretation of the in vivo data presented
is very much hampered by the fact that
Schlumpf et al. (1) used nonstandard and
non-GLP protocols, although official guide-
lines have been issued (2). Specifically, we
refer to Schlumpf et al.’s choice of unusual
rat strains (Long-Evans and Nu rats) for the
uterotrophic assay and to the mode of der-
mal administration (pups were totally
immersed in oily solutions of the test com-
pound). Because of the administration 
protocol used by Schlumpf et al. (1), the cal-
culation of the absorbed dose after dermal
exposure remains obscure. Also, the time of
administration of the test compounds (post-
natal day 26) was very close to or at the
onset of puberty in most rat species.
Following established protocols and
GLP procedures, a uterotrophic assay was
performed in Sprague-Dawley rats (the
standard strain) using three daily doses of
10, 100, or 1,000 mg/kg 4-MBC subcuta-
neously (3); no uterotrophic response was
observed. In another uterotrophic assay (4),
Bp-3 and OMC were tested in female
immature Wistar rats. Bp-3 was adminis-
tered in four oral doses of 500 and 1,000
mg/kg/day, and OMC was applied in three
oral doses of 500 and 1,000 mg/kg/day; no
uterotrophic effect was observed (4). Strain
variations such as these are not entirely
unusual.
According to Table 3 of Schlumpf et al.
(1), effective oral doses (uterotrophic effect)
were 0.342 µg/kg/day ethinylestradiol, 119
mg/kg/day 4-MBC, 1,035 mg/kg/day
OMC, and 1,525 mg/kg/day Bp-3. The
lower doses tested, (i.e., 0.085 µg/kg/day
ethinylestradiol, 66 mg/kg/day 4-MBC,
522 mg/kg/day OMC, and 937 mg/kg/day
Bp-3) must be regarded as no-hormonal-
effect levels (NHELs), based on the data of
Schlumpf et al. (1). The effect of Bp-3
(called “weak” by the authors) appears in a
range above the “limit dose,” according to
current Organisation for Economic Co-
operation and Development guidelines (2).
A very weak effect of Bp-3 is not considered
contradictory with negative findings in
other studies (5), and it appears consistent
with an estrogenic effect of the minor Bp-3-
metabolite p-hydroxy-benzophenone (6),
which comprises ≈ 1% of a benzophenone
dose in rats (7). 
Although the data of Schlumpf et al. (1)
are in contrast to findings of others and
have technical shortcomings, they can nev-
ertheless be incorporated into risk assess-
ment scenarios leading to worst-case views.
We used the data presented by Schlumpf et
al. in their Table 3 (1) as the basis of two
assessments: a) we calculated a traditional
margin of safety (MOS) based on the
NHEL observations of Schlumpf et al., and
b) we compared the estrogenic load that
might be imposed on the human organism
by the UV filter compounds under consid-
eration with the estrogenic load imposed by
phytoestrogens in the normal diet [hygiene-
based margin of safety (HBMOS)] (8).
Official exposure scenarios for 4-MBC and
OMC have been described by the Scientific
Committee of Cosmetic Products and
Non-Food Products (SCCNFP) of the
European Union as a basis of associated risk
assessments (9,10).
The effects of Bp-3 in the study by
Schlumpf et al. (1) are very much border-
line if one considers that they are observed
only at doses above the limit dose. Hence,
the subsequent assessments are restricted to
the two compounds (4-MBC and OMC)
for which uterotrophic effects at lower doses
have been reported by Schlumpf et al. (1).
With regard to human toxicity, experi-
mentally based no-observed-adverse-effect
levels (NOAEL) are the toxicologic key
element. In contrast to other approaches,
the MOS methodology of the European
Union does not make use of numerically
fixed assessment factors; the MOS is calcu-
lated by comparing the level of human
exposure (estimated to a large extent by
modeling) with the NOAEL from animal
experiments.
Application of this concept to hormon-
ally active compounds (endocrine modula-
tors) is easily possible if the hormonal effect
is considered the critical toxicity; this would
mean that NHELs could serve as specific
substitutes of the NOAEL (11). In princi-
ple, this avenue of thinking has been
advanced from the scientific side in discus-
sions concerning regulations of hormonally
active growth promoters in meat (12).
An MOS can be derived by comparing
the NHEL data of the two substances 4-
MBC and OMC from Table 3 of Schlumpf
et al. (1) with official exposure scenarios
(systemic exposure doses) of the SCCNFP
(Table 1) (9,10). 
Bolt et al. (8) developed a supplementary
route of comparative risk calculation using
the concept of HBMOS. Basically, they
compared exposure scenarios for individual
industrial compounds with those of
endocrine modulators of natural origin,
under consideration of the respective relative
potency ratios in vivo. 
The dietary intake figures of estrogenic
isoflavones have been assessed in our labo-
ratory (8); data in the published literature
are in general support of the scenario of the
Senate Commission on the Evaluation of
Food Safety of the Deutsche Forschungs-
gemeinschaft (SKLM) (13), which arrived
at a human daily intake of isoflavones in
the order of 1 mg/kg body weight. 
Relative estrogenic potency assessment
figures based on in vivo studies of 4-MBC
and OMC, in relation to isoflavones (e.g.,
daidzein), can be derived from a synopsis of
the results of the uterotrophic assays by
Schlumpf et al. (1) (shown in their Table 3;
the potencies of 4-MBC and OMC com-
pared to that of ethinylestradiol) and by
Bolt et al. (8). The latter data refer to
uterotrophic assays by Diel et al. (14) that
compare the potencies of the phytoestrogen
daidzein and the reference compound
ethinylestradiol, as well as other compounds.
Based on the concept of “dose addi-
tivity” for combinations of similarly acting
compounds (15), Schlumpf et al. (1) pro-
vide data in their Table 3 of equally effec-
tive doses of ethinylestradiol, 4-MBC, and
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Table 1. Comparison of NHEL data used by Schlumpf et al. (1) and NOAEL data. 
Compound NHEL NOAEL
4-MBC NHEL = 66 mg/kg/day (1) NOAEL (subchronic oral rat study) =
25 mg/kg/day (10)
SED = 0.23 mg/kg (10) SED = 0.23 mg/kg (10)
MOS = NHEL/SED = 290 MOS = NOAEL/SED = 110
OMC NHEL = 522 mg/kg/day (1) NOAEL (13-week rat oral study) =
450 mg/kg/day (9)
SED = 0.6 mg/kg (9) SED = 0.6 mg/kg (9)
MOS = NHEL/SED = 870 MOS = NOAEL/SED = 750
SED, systemic exposure dose.OMC: A daily (4-day) dose of 0.342 µg/kg
ethinylestradiol produced a mean uterine
weight of 37.02 mg. By interpolation
between experimental data points, it
appears that the same uterine weight
(37.02 mg) is elicited by 275 mg/kg
4-MBC or by 1,243 mg/kg OMC. It fol-
lows that ethinylestradiol is more potent
than 4-MBC by a factor of 8 × 105, and is
more potent than OMC by a factor of 3.6
× 106. Using uterotrophic assay data in rats
(14), Bolt et al. (8) concluded that
ethinylestradiol was 40,000 times more
potent than the typical isoflavone phyto-
estrogen daidzein. It follows that the rela-
tive potencies related to daidzein (set to 1)
are 0.05 for 4-MBC and ≈ 0.01 for OMC.
The potency of daidzein is 20-fold higher
than that of 4-MBC and 100-fold higher
than that of OMC.
The official exposure scenario for
isoflavone phytoestrogens (e.g., daidzein) in
European diets by the SKLM was 1 mg/kg
daily. Official exposure scenarios for UV
filter substances in cosmetic products have
been issued by the SCCNFP (9,10). The
HBMOS figures, derived from official sce-
narios, are 87 for 4-MBC (20 mg/kg:0.23
mg/kg) and 167 for OMC (100 mg/kg:0.6
mg/kg).
Three approximations to safety margins
of the UV filters 4-MBC and OMC have
been deduced: 
1. Calculations of MOSs based on the exper-
imental NHELs of Schlumpf et al. (1)
2. The official MOS data of the SCCNFP
based on NOAEL figures from animal
studies under repeated dosage 
3. Application of the novel concept of
HBMOS, which basically compares the
estrogenic load by phytoestrogens in the
diet to that of the compound in question
under application conditions. 
Table 2 provides a summary of these
calculations. The calculations 1 and 3 are
based on the data set of Schlumpf et al. (1),
and calculation 2 is the official assessment
of the SCCNFP (9,10).
The risk assessment data seem to be
consistent with each other. Thus, it must
reasonably be concluded that, considering
the data provided by Schlumpf et al. (1),
even with their technical shortcomings, the
resulting margins of safety for the com-
pounds in question clearly provide suffi-
cient safety under the conditions of use. 
Hermann M. Bolt 
Christine Guhe
Gisela H. Degen
Institute of Occupational Physiology at the
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“In Vitro and in Vivo
Estrogenicity of UV Screens”:
Response 
We thank EHP for the opportunity to
respond to the comments of Bolt and co-
workers. Because Bolt et al. question our
data on methodologic grounds and their
use for risk assessment, we will deal with
these two aspects separately.
Bolt et al. state that 
in vitro data should serve only for screening pur-
poses and that they are not suited for conclusions
regarding risk assessment. 
This should be clear from our paper. In
vitro experiments certainly are not meant to
serve for risk assessment; however, it is gen-
erally accepted that positive in vitro findings
should lead to additional in vivo studies. 
The oral experiments were conducted
between spring and fall 1999. In contrast to
Bolt et al.’s statement, there is still not an
official guideline for the uterotrophic assay.
The Endocrine Disrupters Testing and
Assessment (EDTA) Task Force of the
Organisation for Economic Co-operation
and Development (OECD) decided on a
proposal for the preparation of a guideline
at its meeting held 26–27 May 2001.
Bolt et al. believe that our use of Long-
Evans rats was not acceptable for our study.
To our knowledge, the OECD protocol (1)
will not specify the rat strains to be used for
the uterotrophic assay. Long-Evans rats
have long been used in neuroendocrine and
endocrine investigations. The hairless
(hr/hr) strain was recommended to us for
dermatologic studies by a European breed-
ing institute. Because we used this strain,
we were able to use Aghazarian et al.’s (2)
recent rat skin penetration data, which were
obtained on skin of the same strain, for a
provisional estimation of dermal dosage.
The hr/hr rats are derived from the OFA
(Oncins France)-SD (Sprague Dawley)
strain (IFFA CREDO, L’Arbresle, France). 
We used dermal application by immer-
sion in warm olive oil after discussing the
method with other endocrine disruptor
experts. We chose this method mainly for
the following reason: The surface on the
back of the immature animal available for
application of compound is much smaller
than in adult rats, and plasters that would
not unduly disturb the immature animals
could easily be removed by the littermates
in the cage. When working with immature
animals, a major requirement is avoidance
of stress. The OECD protocol (1) also rec-
ommends group housing “because single
housing of immature animals may cause
considerable stress.” The procedure of
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Table 2. Calculations of MOSs by three different methods.
12 3
Compound MOS [NHEL] MOS [NOAEL] HBMOS
4-MBC 290 110 87
OMC 870 750 167immersion, carried out very gently, was well
tolerated by the animals.
Irrespective of the method used to cal-
culate the dermally applied dose, the
amount taken up by the animal can never
be calculated with the same precision as
with the oral or parenteral routes from the
amount applied. The only solution is the
determination of blood and tissue levels,
which presently is in progress in our labo-
ratory using gas chromatography-mass
spectrometry. 
As we stated in our paper (3), experi-
ments were conducted on offspring of time-
pregnant rats. We recorded birth [occurring
in the morning of gestational day (GD) 23,
which is also postnatal day (PN) 1; GD 1 =
24 hr after mating period]; pups were then
culled to eight per litter and observed daily.
The development of uterine weight was
studied in detail between PN20 and PN32
in Long-Evans and hairless rats (4). These
data clearly show that in both strains, uterine
weight remains at the same level until PN
26. Thus, PNs 25 and 26 can be used in our
strains. This is also evident from an analysis
of histograms of frequency distributions of
individual uterine weights in controls and
treated groups from oral and dermal studies
investigated at PNs 25 and 26 (5). 
With respect to OMC and Bp-3, our
data are in full agreement with the data
quoted by Bolt et al. The oral no-hormonal-
effect levels Bolt et al. compared to our data
were as follows: 250 vs. 522 mg/kg/day for
OMC and 1,000 vs. 937 mg/kg/day for
Bp-3. The lowest-observable-effect levels
were 103 mg/kg/day for OMC and 1,525
mg/kg/day for Bp-3 in our oral study. The
only difference is with 4-MBC, where no
effect was seen after treatment with up to
1,000 mg/kg/day in the study quoted by
Bolt et al., whereas we observed a significant
increase in uterine weight at 119 mg/kg/day.
Apart from rat strain, the main difference
between the two studies is the route of appli-
cation, subcutaneous versus oral (2). Even
though the subcutaneous route is thought to
be slightly more sensitive in the uterotrophic
assay, this may not be the case for all com-
pounds. Controversial uterine weight data
also exist for other chemicals with proven
binding and transcriptional activity at estro-
gen receptors. This issue cannot yet be con-
sidered to be completely settled. In some
cases with negative uterine weight data,
other estrogen-sensitive parameters were
influenced by the compound (6). Recently,
we corroborated increased uterine cell prolif-
eration following dermal application of
4-MBC and OMC by demonstrating
increased bromodeoxyuridine uptake (4,5). 
In our view, Bolt et al. make inappropri-
ate use of our data. There is international
agreement that the uterotrophic assay can
only serve a limited function as a test for in
vivo identification of chemicals with estro-
genic (or antiestrogenic) activity. To our
knowledge, the uterotrophic assay is situat-
ed between in vitro screening tests and long-
term studies (e.g., TG416) in the scenario
for the investigation of endocrine disruptors
conceived by the EDTA committee of the
OECD, which initiated the validation of
this test. The uterotrophic assay typically is
an acute high-dose test. As discussed in
detail in our paper (3), other known xeno-
estrogens such as methoxychlor, nonylphe-
nol, bisphenol A, and o,p´-DDT also need
to be applied at similar high doses to
achieve a significant growth of the uterus in
a few days (7–10). If one considers the com-
plex organizational and activational actions
of steroid hormones at different stages of
the life cycle, it becomes clear that such
acute data cannot provide a basis for long-
term risk calculations. In view of possible
differences in gene regulation patterns, it is
also not possible to draw conclusions on
long-term risk from a comparison of
dosages of different estrogenic chemicals.
At first sight, it seems tempting to relate
estrogenic activities of different chemicals to
a phytoestrogen occuring in food and to use
this for a unified evaluation of “in vivo
estrogenicity.” However, this concept pre-
sents serious scientific flaws, in particular
with regard to an application to long-term
effects. It is evident from the scientific liter-
ature of the last 10–15 years that estrogenic
chemicals are not alike. First of all, there are
important differences in toxicokinetics that
are not considered by comparing daily
intake. In addition, and this may be more
important, estrogenic chemicals can differ
markedly in their effects on gene regulation,
not only quantitatively but also qualitative-
ly. It is well known that even closely related
chemicals, such as tamoxifen and raloxifene,
exhibit different tissue selectivity, acting as
agonist (tamoxifen) or antagonist (ralox-
ifene) in one and the same tissue (uterus)
(11). Moreover, different compounds with
agonistic or partial agonistic activity at
estrogen receptors can recruit different coac-
tivators/corepressors (11,12), and elicit dif-
ferent gene induction patterns, for example,
in the uterus (13). In a recent study on
adult ovariectomized rats (14), the effect of
daidzein on mRNA expression in uterus dif-
fered qualitatively (up- or down-regulation)
from that of bisphenol A for three out of six
genes studied, and for DDT for two out of
six genes. These differences in effects on
gene regulation are not consistently revealed
by simple measures of estrogenicity such as
proliferation of cell lines or uterine growth.
They may well matter in particular with
long-term exposure. As a consequence, the
principle of using a phytoestrogen such as
daidzein (or ethinylestradiol) as a reference
compound for estrogenic activity and
extrapolating from the activity ratio calcu-
lated from acute data to long-term risk of
chemicals with a different structure cannot
be considered to represent a valid approach.
In our paper (3), we reported on acute
in vitro and in vivo estrogen-like effects of
UV screens. We deliberately abstained from
extrapolation of these acute data to long-
term exposure in view of risk assessment
because this could not be considered to be
scientifically sound on the basis of present
knowledge. Much to our surprise, this is
being done now by colleagues from both
academia and industry. In our view, the cal-
culation of safety margins for chronic expo-
sure from our acute data is not acceptable
on scientific grounds.
We insist that the effect levels of five
UV screens in vitro and three compounds
in the uterotrophic assay are in the range of
other chemicals for which there is general
agreement on the need for long-term stud-
ies on possible endocrine effects. Hence, we
think that a solid risk assessment requires
additional long-term studies, with particu-
lar reference to endocrine parameters, and a
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The Full Circle: From the
Minamata Disaster to the Sick
Building Syndrome 
Pekkanen and Pearce (1) recently focused on
the challenges and opportunities of environ-
mental epidemiology. Their paper recalls to
our minds the fascinating story of humans
and environment: they continuously look
for the best milieu for their lives. First, they
think that industrialized areas are better
than natural areas; then they reason that
returning to the natural environment is
probably better, always being sure that each
choice is the safest. However, no choice
allows environmental risks to be completely
abolished, and the only way to cope with
the problem of environmental risks is to
face them [as Pekkanen and Pearce (1) did,
by looking for the best studies to evaluate
these risks], not to believe they have been
blunted.
Can you imagine a paradise better than
that of Minamata Bay, facing the Shiranui
Sea in Japan? It has blue sea, white sand,
green shrubs, burning sun, and bright stars.
But in the mid-1950s, some unexplainable
occurrences brought panic to Minamata:
birds were strangely dropping from the sky,
cats committed “suicide,” and people began
to notice a “strange disease” that caused
numbness in limbs and lips, slurring of
speech, vision constriction, uncontrollable
shouting, involuntary movements, and
unconsciousness.
The risk came from 27 tons of mercury
compounds dumped into Minamata Bay
from 1932 to 1968 by a company develop-
ing plastic, drugs, and perfumes, through
the use of acetaldhyde, which is produced
using mercury. Over 3,000 victims suffering
from degeneration of the nervous system
have been recognized as having Minamata
disease (2,3). 
Paradise was only a dream; good health
in a pure, uncontaminated area cannot con-
tinue in the absence of safety controls. 
Humans thought they had learned the
lesson and began to construct safer build-
ings, as a modern paradise with many com-
forts and far from environmental risks. But,
in the mid-1970s, some unexplainable
occurrences brought concern: people living
in recently built houses began to suffer
somatic and psychological symptoms,
including arthralgia, eye and throat irrita-
tion, cough, rash, pruritus, enhanced and/or
abnormal odor perception, visual distur-
bances, mild to severe headache, nausea,
vomiting, restlessness, and sleeplessness.
Some volatile component of the building
materials or some biological contaminant
(perhaps endotoxin, mycotoxin, or trace ele-
ments) might be causing this unique sys-
temic syndrome, the so-called sick building
syndrome (4,5).
This constructed perfection was also a
dream. Good health in an artificial, sophisti-
cated structure is not guaranteed even in the
presence of better safety controls, or perhaps
by the presence of modern technological
devices such as humidifiers and ventilation
systems.
Nature is less perfect and more vulnera-
ble than we used to surmise; for humans
living on the earth crust, each new direction
has its disadvantages. Can people win
against the environment? Looking at envi-
ronmental epidemiology with its opportuni-
ties and challenges (1) is a largely better
approach than that of dreaming about
unlikely simple and perfect solutions, such
as that of coming back to pure, uncontami-
nated nature or waiting for a completely
technology-modified environment.
Human life, either “natural” or indus-
trialized, has some challenges, as both the
Minamata disaster and the sick building
syndrome demonstrate. A concern for sick
building syndrome does not justify the
claim that pure uncontaminated nature
(including Minamata Bay or fresh unsteril-
ized milk often containing tuberculosis bac-
teria) is the best goal for humans. A logical
and scientific approach to the problem,
such as that offered by Pekkanen and
Pearce (1), must be shared because it offers
the only possibility for humans to survive.
Living without risks is impossible, but low-
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